The Investor
28 Apr 2026, 19:13
Gilead Sciences announced it has completed its acquisition of Arcellx Inc. in a deal valued at approximately $7.8 billion, strengthening its oncology portfolio.
The transaction gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma, allowing the company to streamline development and maximize long-term value by eliminating profit-sharing and royalty obligations.
Gilead said the deal is expected to be dilutive to earnings in 2026 and 2027 but accretive from 2028 onward, subject to regulatory approval of the therapy. Arcellx will now operate as a wholly owned subsidiary of Gilead.
Source: Gilead Sciences press release, Business Wire
The transaction gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma, allowing the company to streamline development and maximize long-term value by eliminating profit-sharing and royalty obligations.
Gilead said the deal is expected to be dilutive to earnings in 2026 and 2027 but accretive from 2028 onward, subject to regulatory approval of the therapy. Arcellx will now operate as a wholly owned subsidiary of Gilead.
Source: Gilead Sciences press release, Business Wire